Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about New antiretroviral drugs decrease chances of HIV sexual transmission
More than 2 million people got infected by human immunodeficiency virus (HIV) in 2015, being sexual transmission the main channel of infection. Researchers from the Infections of the Respiratory Tract and in Immunocompromised Patients group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Daniel Podzamczer, have evaluated the speed at which a new antiretroviral drug, Dolutegravir, is able to reduce the viral load in semen, an area of the body considered to be a reservoir of the virus and where access for drugs is more difficult. The results, published in Journal of Infectious Diseases, show the potential of these new treatments to reduce the chances of sexual transmission of the virus.
- Read more about Pembrolizumab in lung cancer: Indication of considerable added benefit
Pembrolizumab (trade name: Keytruda) was initially introduced for the treatment of melanoma. Since July 2016, the monoclonal antibody has also been available for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy also for these patients.
- Read more about Adding ADHD drug to therapy improves cognitive outcomes in traumatic brain injury patients
INDIANAPOLIS - A combination of the stimulant drug methylphenidate with a process known as cognitive-behavioral rehabilitation is a promising option to help people who suffer from persistent cognitive problems following traumatic brain injury, researchers at Indiana University School of Medicine have reported.
- Read more about U.S. FDA Grants Fast Track Designation to Oragenics’ AG013 for Oral Mucositis
Oragenics announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to AG013, the Company’s lead therapeutic candidate for the treatment of OM. Oragenics expects to file an Investigational New Drug (IND) update and initiate a Phase 2 study with AG013 in the United States and Europe in early 2017.
- Read more about SuperSonic Imagine’s Aixplorer® Ultrasound System Added to Knoxville Comprehensive Breast Center
SuperSonic Imagine announced the installation of its flagship Aixplorer ultrasound system at Knoxville Comprehensive Breast Center in Tennessee. The Aixplorer system provides premium breast imaging and unique innovations including real-time ShearWave™ Elastography (SWETM).
- Read more about Novartis acquires Selexys Pharmaceuticals Corporation
Novartis announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD). Results from the study will be presented during the Plenary Scientific Session at the 58thAmerican Society of Hematology (ASH) Annual Meeting on December 4, 2016, in San Diego, California.
- Read more about Aduro Biotech announce U.S.FDA lifted Partial Clinical Hold on LADD Clinical Trials
Aduro Biotech, Inc. ,a biopharmaceutical company with three distinct immunotherapy technologies, announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on its clinical trials evaluating the LADD (live, attenuated double-deleted) immunotherapy platform, enabling patient enrollment to resume in all Aduro-sponsored clinical studies.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Study confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced the publication of the EGALITY study in the British Journal of Dermatology. The confirmatory clinical safety and efficacy study shows Sandoz biosimilar etanercept is equivalent to the originator product, Enbrel®***, in more than 500 adult patients over 52 weeks.
- Read more about Spectrum Pharma’s Poziotinib data presentation at the 17th IASLC world conference
Spectrum Pharmaceuticals announced that scientists from MD Anderson Cancer Center will be presenting data from a preclinical study evaluating poziotinib in lung cancer at the 17th International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer taking place in Vienna, Austria, December 4-7, 2016.
- Read more about Sorrento's TNK Therapeutics Subsidiary Acquire Virttu Biologics
TNK Therapeutics, Inc, a subsidiary of Sorrento Therapeutics, Inc has entered into a binding term sheet to acquire Virttu Biologics Limited ("Virttu").